The businesses Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the most important biotech funding rounds general in Could 2026 throughout non-public and public funding sorts. On this article, we break down final month’s non-public and public fundraising exercise, wanting on the largest rounds in additional element.
Non-public biotech funding rounds in Could 2026
First, let’s check out the non-public biotech investments in Could 2026, breaking them down by worth, location, funding sort, and therapeutic subsector.
Largest non-public biotech funding rounds by worth
Final month, Isomorphic Labs raised a staggering $2.1 billion in sequence B funding. The corporate helped Google DeepMind to develop the acclaimed synthetic intelligence (AI) mannequin AlphaFold3, which may precisely predict the 3D construction of proteins. It now intends to make use of the proceeds from this financing for the continued improvement and deployment of its AI drug design engine (IsoDDE), accelerating and increasing its pipeline of therapeutic applications in the direction of the clinic.
In one other blockbuster financing, Apogee Therapeutics secured as much as $1.3 billion in versatile, non-dilutive capital final month from Blackstone Life Sciences, together with as much as $800 million in artificial royalty and entry to as much as $500 million in senior company debt. A part of the financing will go towards section 3 improvement of Apogee’s lead candidate, zumilokibart, for the remedy of atopic dermatitis.
In the meantime, CellCentric got here third in Could’s non-public biotech funding rankings after elevating $220 million in sequence D funding to assist the development of its lead candidate inobrodib via pivotal scientific improvement research, together with the continued enrollment of the corporate’s not too long ago initiated section 2 research within the U.Okay. and U.S., and the initiation of a world section 3 trial within the second half of 2026.
Non-public biotech funding rounds by location
We witnessed an enormous shock in Could when funding rounds by location. For as soon as, North American firms didn’t carry within the largest sum of money; as a substitute, it was Europe that gained the competition. Whereas each areas achieved 5 rounds every, European firms bagged a complete of $2.718 billion – roughly $1.2 billion greater than North American firms. This was largely because of U.Okay.-based Isomorphic’s $2.1 billion sequence B spherical.
Non-public biotech funding rounds by funding sort
Final month, sequence B rounds got here out on prime when wanting on the largest quantity raised, as they introduced in a complete of $2.222 billion, whereas sequence A funding achieved probably the most rounds, with three in complete. Non-dilutive funding then got here second when it comes to worth attributable to Apogee’s $1.3 billion financing settlement.
Non-public biotech funding rounds by therapeutic subsector
Regardless of the therapeutic subsectors of immunological illnesses and oncology reaching probably the most rounds, with three every, it was AI and inflammatory illnesses – courtesy of Isomorphic’s and Apogee’s large financings – that introduced within the largest quantities of cash, respectively.
Public biotech funding rounds in Could 2026
Now, let’s take a look at the general public biotech fundraising rounds that occurred in Could 2026, breaking them down by worth and therapeutic subsector.
Public biotech funding by worth
It was a brief record for public biotech fundraisings final month, as solely 4 important rounds passed off.
In first place was Avalo Therapeutics, which priced a $375 million public providing to advance the scientific improvement of its candidate abdakibart, together with via its section 3 topline knowledge launch. In the meantime, in second place, gene modifying firm Editas Drugs introduced a public providing of as much as $319.4 million, and, in third place, immunology firm Odyssey Therapeutics raised $304 million from an preliminary public providing (IPO) and concurrent non-public placement.
It’s additionally price noting that Artiva Biotherapeutics wasn’t far behind in fourth place after pricing a $300 million underwritten providing.
Public biotech funding by therapeutic subsector
Final month, the subsector of immunological illnesses got here out on prime, attracting two rounds and $604 million in complete. In second place, inflammatory illnesses introduced in $375 million, and, in third place, cardiovascular illnesses attracted $319.4 million.
Month-to-month comparability of biotech fundraising
Under is a graph displaying a month-to-month comparability of personal and public biotech fundraising, wanting on the complete sum of money raised per 30 days in 2026.
The quantity of personal fundraising achieved in Could was fairly unbelievable, with firms bringing in a complete of $4.265 billion. This was, after all, largely because of the 2 large funding rounds by Isomorphic Labs and Apogee Therapeutics. Moreover, though the general public fundraising panorama solely noticed 4 important rounds final month, the overall quantity raised was nonetheless pretty spectacular, coming in at $1.298 billion – which was greater than March’s complete, regardless of there being far fewer rounds.
